Redx to Present at the AACR Annual Meeting

REDX PHARMA PLC

("Redx" or "the Company")

Redx to Present at the American Association for Cancer Research (AACR) Annual Meeting

Alderley Park, 24 March 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces it will present a poster entitled 'Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies' on 12 April 2022 at the forthcoming hybrid American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, US on 8-13 April 2022.

The poster will present preclinical data on the potential benefits of RXC004, Redx's lead oncology asset, in combination with clinically relevant standard of care chemotherapy regimens. RXC004 is a potent, orally active porcupine inhibitor in clinical development as a targeted therapy for Wnt-ligand driven cancer. It is currently in Phase 1 clinical studies in combination with nivolumab, an anti-PD-1 antibody, and is also being evaluated as a monotherapy in Phase 2 proof-of-concept clinical studies for the treatment of genetically selected pancreatic cancer, genetically selected metastatic colorectal cancer and unselected biliary cancer.

The abstract is available via the AACR Annual Meeting website at: https://www.abstractsonline.com/pp8/#!/10517/presentation/15373 

The poster will be available from Friday 8 April on the AACR e-poster website and the investor section of the Company's website at: https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/ 

About Redx Pharma Plc 

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data has been reported, and a Phase 2 clinical programme is confirmed to start in 2022.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/